Price Estimate, page-35

you are correct in that there are differences, it is more a question of how the market will value those differences against which stock is more product ready etc.

There is a lot of new shares now, the total valuation at 8c would be 250million, which we still haven't seen the revenue numbers from MCL and we have to assume that Medcan has only just, or is about to start cultivating their crop so no revenue either.

Bauxite is worthless IMO, I won't repeat myself as to why but I've made it pretty clear I feel this is a weed stock with a bauxite name.

The major thing for me that sticks out, is the price tag of MCL. QBL had 55% already, so owned the majority of the profits from future ventures as well as had a controlling say at the table. They paid 60million at current prices for the additional 45%. They also paid 12.5million to MedCan and expect to pay an additional 9million in product development this year.

That means shareholders just paid 81.5million dollars.. at current prices. Seems quite high on the valuation end, but maybe it is meant to drive the right behaviors, i.e. all of the parties see value in making money for the entire venture.

I guess we shall see.